Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries

MerckMerck, a leading science and technology ­company, is celebrating its anniversary by conducting 350 charitable activities in around 60 countries. Taking responsibility has always been an integral part of the entrepreneurial approach of Merck and is one of its six values. On the occasion of its 350th anniversary, the company will further intensify its social engagement activities together with its employees.

"We have a long tradition of responsibility, it’s more than just lip service. That's why we want to share the great joy of our anniversary not only with our employees, but also with our local communities," said Walter Galinat, member of the Executive Board of Merck and responsible for the 350th anniversary celebrations. "We take on responsibility for society all over the world. Many of our employees and subsidiaries are involved in this effort, for instance through donations, collaborations with reliable partners and voluntary initiatives," he added.

The activities planned to take place throughout 2018 will focus on health as well as on education and culture. Here, Merck will leverage its 350 years of experience and curiosity, as well as its knowledge and expertise in the areas of health, science and technology. In addition to these efforts, the company also supports a wide array of charitable and environmental initiatives in the communities near its sites and provides disaster relief. The aim is to address challenges facing society, from fighting serious diseases and protecting natural resources to promoting aspiring young scientists.

The projects in the focus area of health are centered around developing local healthcare infrastructure, providing vocational and advanced training to medical staff and raising awareness of health issues. Founded in 2017, for instance, the Merck Foundation supports initiatives to improve the treatment of cancer patients in Africa. And in Guatemala, Merck is working with an organization that provides free healthcare to underprivileged communities and helps people with disabilities.

Within the focus area of education, particular emphasis is placed on sparking young people's interest in science. A prime example is the SPARK volunteer program, under which employees conduct scientific experiments with school children in an effort to arouse their curiosity. A large number of activities are also taking place in Darmstadt, where the company is headquartered. These include an exciting experiment afternoon for school students to mark the tenth anniversary of the Junior Laboratory at the Technical University of Darmstadt. In Indonesia, Merck is supporting the charitable organization Nara Kreatif, with which it is collaborating on environmental and educational projects. These include a school for 300 children in need, at which Merck employees are also volunteering.

Within the focus area of culture, Merck is often engaged in projects that transcend cultural borders, such as a literature initiative in Korea that encourages exchange between Germany and several Asian countries.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

FDA grants priority review to Roche's cancer immun…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) a...

Kymriah® (tisagenlecleucel), first-in-class CAR-T …

Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication ...

Daily aspirin linked to higher risk in men

Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin, reports a new Northwestern Medicine study. W...

New leads on treating dementia and Alzheimer's

A new research study by scientists in Australia and the US provides an explanation for why clinical trials of drugs reducing proteins in the brain that were thought to ca...

Roche reports a strong start in 2018

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division in...

To treat pain, you need to treat the patient

People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depr...

Novo Nordisk participates in new research project …

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find bet...

Chemical octopus catches sneaky cancer clues, trac…

Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until n...

Alcon Cares Project 100 commits to reducing catara…

Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to ...

FDA approves novel preventive treatment for migrai…

The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly se...

First clues to the causes of multiple sclerosis

Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision...

Doctors in US and Canada launch sweeping pharmaceu…

The skyrocketing cost of prescription drugs is one of the biggest concerns for American voters. However, in his proposal last Friday, President Donald Trump failed to off...